
2care4 Generics ApS

Stenhuggervej 12, DK-6710 Esbjerg V

Annual Report for 1 January - 31 December 2021

CVR No 36 96 05 66

The Annual Report was
presented and adopted at
the Annual General
Meeting of the Company on
17/5 2022

Thomas Hjarsbæk
Rasmussen
Chairman of the General
Meeting



pwc

Contents

	<u>Page</u>
Management's Statement and Auditor's Report	
Management's Statement	1
Independent Auditor's Report	2
Company Information	
Company Information	5
Management's Review	6
Financial Statements	
Income Statement 1 January - 31 December	7
Balance Sheet 31 December	8
Statement of Changes in Equity	10
Notes to the Financial Statements	11

Management's Statement

The Executive Board and Board of Directors have today considered and adopted the Annual Report of 2care4 Generics ApS for the financial year 1 January - 31 December 2021.

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2021 of the Company and of the results of the Company operations for 2021.

In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Esbjerg, 17 May 2022

Executive Board

Ulrik Ernst Rasmussen
CEO

Board of Directors

Henrik Bisgaard Jensen

Toke Værndal

Independent Auditor's Report

To the Shareholders of 2care4 Generics ApS

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2021 and of the results of the Company's operations for the financial year 1 January - 31 December 2021 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of 2care4 Generics ApS for the financial year 1 January - 31 December 2021, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies ("the Financial Statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the Financial Statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financials Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Management's responsibilities for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstate-

Independent Auditor's Report

ment, whether due to fraud or error.

In preparing the Financial Statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the Financial Statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events

Independent Auditor's Report

in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Esbjerg, 17 May 2022

PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

CVR No 33 77 12 31

Palle H. Jensen
statsautoriseret revisor
mne32115

Stefan Dracea
statsautoriseret revisor
mne42827

Company Information

The Company

2care4 Generics ApS
Stenhuggervej 12
DK-6710 Esbjerg V

CVR No: 36 96 05 66
Financial period: 1 January - 31 December
Incorporated: 10 July 2015
Financial year: 6th financial year
Municipality of reg. office: Esbjerg

Board of Directors

Henrik Bisgaard Jensen
Toke Værndal

Executive Board

Ulrik Ernst Rasmussen

Auditors

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Esbjerg Brygge 28
DK-6700 Esbjerg

Management's Review

Key activities

The main activity of the company is to develop, import, produce, negotiate and export pharmaceutical products and thus naturally related business.

Development in the year

The income statement of the Company for 2021 shows a profit of DKK 29,082,540, and at 31 December 2021 the balance sheet of the Company shows equity of DKK 44,631,599.

The past year and follow-up on development expectations from last year

The activity level and profit in 2021 has increased compared to 2020. Many of the developed projects has reached market, and had a positive impact on the gross profit.

Research and development

The development of the company includes implemented measures that within a few years is expected to generate increased revenue for the company.

Subsequent events

No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.

Income Statement 1 January - 31 December

	Note	2021 DKK	2020 DKK
Gross profit/loss		55.862.884	32.852.182
Staff expenses	1	-14.422.613	-11.480.140
Depreciation, amortisation and impairment of intangible assets and equipment	2	-5.280.162	-2.189.630
Profit/loss before financial income and expenses		36.160.109	19.182.412
Financial income	3	571.138	408.327
Financial expenses	4	-475.131	-335.823
Profit/loss before tax		36.256.116	19.254.916
Tax on profit/loss for the year	5	-7.173.576	-3.540.292
Net profit/loss for the year		29.082.540	15.714.624

Distribution of profit

Proposed distribution of profit

Proposed dividend for the year	5.000.000	0
Retained earnings	24.082.540	15.714.624
	29.082.540	15.714.624

Balance Sheet 31 December

Assets

	Note	2021 DKK	2020 DKK
Completed development projects		6.963.158	6.625.522
Acquired licenses		1.404	31.118
Development projects in progress		<u>28.118.268</u>	<u>21.262.307</u>
Intangible assets	6	<u>35.082.830</u>	<u>27.918.947</u>
Other fixtures and fittings, tools and equipment		<u>236.137</u>	<u>402.787</u>
Property, plant and equipment	7	<u>236.137</u>	<u>402.787</u>
Deposits		<u>45.900</u>	<u>0</u>
Fixed asset investments	8	<u>45.900</u>	<u>0</u>
Fixed assets		<u>35.364.867</u>	<u>28.321.734</u>
Inventories	9	<u>22.497.851</u>	<u>14.973.646</u>
Trade receivables		19.094.226	15.809.714
Receivables from group enterprises		47.741.199	10.951.468
Other receivables		<u>1.102.412</u>	<u>1.090.085</u>
Receivables		<u>67.937.837</u>	<u>27.851.267</u>
Cash at bank and in hand		<u>1.973.624</u>	<u>1.285.865</u>
Currents assets		<u>92.409.312</u>	<u>44.110.778</u>
Assets		<u>127.774.179</u>	<u>72.432.512</u>

Balance Sheet 31 December

Liabilities and equity

	Note	2021 DKK	2020 DKK
Share capital		50.000	50.000
Reserve for development costs		27.363.516	21.750.551
Retained earnings		12.218.083	-6.251.492
Proposed dividend for the year		5.000.000	0
Equity		44.631.599	15.549.059
Provision for deferred tax	10	7.282.706	5.479.000
Other provisions		886.000	1.768.000
Provisions		8.168.706	7.247.000
Other payables		0	552.958
Long-term debt	11	0	552.958
Credit institutions		35.291.405	20.598.261
Trade payables		3.983.337	8.096.522
Payables to group enterprises		1.646.726	799.241
Payables to group enterprises relating to corporation tax		5.369.870	2.340.792
Other payables	11	28.682.536	17.248.679
Short-term debt		74.973.874	49.083.495
Debt		74.973.874	49.636.453
Liabilities and equity		127.774.179	72.432.512
Contingent assets, liabilities and other financial obligations	12		
Related parties	13		
Accounting Policies	14		

Statement of Changes in Equity

	Share capital	Reserve for development costs	Retained earnings	Proposed dividend for the year	Total
	DKK	DKK	DKK	DKK	DKK
Equity at 1 January	50.000	21.750.551	-6.251.492	0	15.549.059
Development costs for the year	0	7.447.236	-7.447.236	0	0
Depreciation, amortisation and impairment for the year	0	-1.834.271	1.834.271	0	0
Net profit/loss for the year	0	0	24.082.540	5.000.000	29.082.540
Equity at 31 December	50.000	27.363.516	12.218.083	5.000.000	44.631.599

Notes to the Financial Statements

	2021	2020
	DKK	DKK
1 Staff expenses		
Wages and salaries	13.464.245	10.887.096
Pensions	677.744	432.587
Other social security expenses	112.621	71.420
Other staff expenses	168.003	89.037
	14.422.613	11.480.140
Average number of employees	15	12
<p>Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statements Act.</p>		
2 Depreciation, amortisation and impairment of intangible assets and equipment		
Amortisation of intangible assets	2.495.287	1.997.332
Depreciation of property, plant and equipment	166.650	97.213
Gain and loss on disposal	2.618.225	95.085
	5.280.162	2.189.630
3 Financial income		
Interest received from group enterprises	571.138	0
Other financial income	0	408.327
	571.138	408.327

Notes to the Financial Statements

	2021 DKK	2020 DKK	
4 Financial expenses			
Interest paid to group enterprises	0	62.204	
Other financial expenses	475.131	273.619	
	475.131	335.823	
5 Tax on profit/loss for the year			
Current tax for the year	5.369.870	2.340.792	
Deferred tax for the year	1.803.706	1.199.500	
	7.173.576	3.540.292	
6 Intangible assets			
	Completed development projects DKK	Acquired licenses DKK	Development projects in progress DKK
Cost at 1 January	11.047.660	148.895	21.262.307
Additions for the year	946.339	1.479	11.334.601
Disposals for the year	-210.046	0	-2.520.644
Transfers for the year	1.957.996	0	-1.957.996
Cost at 31 December	13.741.949	150.374	28.118.268
Impairment losses and amortisation at 1 January	4.422.138	117.777	0
Amortisation for the year	2.469.118	31.193	0
Reversal of amortisation of disposals for the year	-112.465	0	0
Impairment losses and amortisation at 31 December	6.778.791	148.970	0
Carrying amount at 31 December	6.963.158	1.404	28.118.268

Notes to the Financial Statements

6 Intangible assets (continued)

	Completed development projects <hr/> DKK	Acquired licenses <hr/> DKK	Development projects in progress <hr/> DKK
Amortised over	<hr/> 5 years	<hr/> 3 years	

Development projects in progress

Development projects in progress comprise development and registration of generic pharmaceutical products. The costs include both external costs to business partners and internal working hours. Costs are registered in an internal project tool. The individual pharmaceutical product will be finished in the years 2022-2025. Afterwards, sales will start up. Overall, the products are expected to contribute with significant competitive advantages and therefore a substantial increase in activity level and result. The management has completed impairment test of the current book value of the assets. The recoverable amount, value in-use, exceeds the book value. Value in-use is calculated from expected cashflows based on management approved budgets through 2022-2025.

Completed development projects

Completed development projects include development and registration of pharmaceutical products for humans. Each product has a 5 year depreciation period, starting from when the product is launched in the market. The management has not established any indication for impairment of the current book value of the assets.

Notes to the Financial Statements

7 Property, plant and equipment

	Other fixtures and fittings, tools and equipment DKK
Cost at 1 January	500.000
Cost at 31 December	500.000
Impairment losses and depreciation at 1 January	97.213
Depreciation for the year	166.650
Impairment losses and depreciation at 31 December	263.863
Carrying amount at 31 December	236.137
Depreciated over	3 years

8 Fixed asset investments

	Deposits DKK
Cost at 1 January	0
Additions for the year	45.900
Cost at 31 December	45.900
Impairment losses at 1 January	0
Impairment losses at 31 December	0
Carrying amount at 31 December	45.900

9 Inventories

	2021 DKK	2020 DKK
Raw materials and consumables	20.392.370	14.815.533
Prepayments for goods	2.105.481	158.113
	22.497.851	14.973.646

Notes to the Financial Statements

10 Provision for deferred tax

Intangible assets	7.718.000	6.142.000
Property, plant and equipment	-12.000	3.000
Inventories	-423.000	-666.000
Tax loss carry-forward	-294	0
	<u>7.282.706</u>	<u>5.479.000</u>

11 Long-term debt

Payments due within 1 year are recognised in short-term debt. Other debt is recognised in long-term debt.

The debt falls due for payment as specified below:

	<u>2021</u> DKK	<u>2020</u> DKK
Other payables		
Between 1 and 5 years	0	552.958
Long-term part	0	552.958
Other short-term payables	28.682.536	17.248.679
	<u>28.682.536</u>	<u>17.801.637</u>

12 Contingent assets, liabilities and other financial obligations

Other contingent liabilities

The group companies are jointly and severally liable for tax on the jointly taxed incomes etc of the Group. The total amount of corporation tax payable is disclosed in the Annual Report of 2care4 Group ApS, which is the management company of the joint taxation purposes. Moreover, the group companies are jointly and severally liable for Danish withholding taxes by way of dividend tax, tax on royalty payments and tax on unearned income. Any subsequent adjustments of corporation taxes and withholding taxes may increase the Company's liability.

Notes to the Financial Statements

13 Related parties

	Basis
Controlling interest	
2care4 Group ApS	Esbjerg

Consolidated Financial Statements

Name and registered office of the Parent preparing consolidated financial statements for the smallest group:

Name	Place of registered office
2care4 Group ApS	Esbjerg

Notes to the Financial Statements

14 Accounting Policies

The Annual Report of 2care4 Generics ApS for 2021 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C.

The accounting policies applied remain unchanged from last year.

The Financial Statements for 2021 are presented in DKK.

Recognition and measurement

Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

Leases

Leases in terms of which the Company assumes substantially all the risks and rewards of ownership (finance leases) are recognised in the balance sheet at the lower of the fair value of the leased asset and the net present value of the lease payments computed by applying the interest rate implicit in the lease or an alternative borrowing rate as the discount rate. Assets acquired under finance leases are depreciated and written down for impairment under the same policy as determined for the other fixed assets of the Company.

The remaining lease obligation is capitalised and recognised in the balance sheet under debt, and the interest element on the lease payments is charged over the lease term to the income statement.

All other leases are considered operating leases. Payments made under operating leases are recognised in the income statement on a straight-line basis over the lease term.

Notes to the Financial Statements

14 Accounting Policies (continued)

Translation policies

Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Exchange differences arising due to differences between the transaction date rates and the rates at the dates of payment are recognised in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognised directly in equity.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the rates at the time when the receivable or the debt arose are recognised in financial income and expenses in the income statement.

Fixed assets acquired in foreign currencies are measured at the transaction date rates.

Income Statement

Revenue

Revenue from the sale of goods is recognised when the risks and rewards relating to the goods sold have been transferred to the purchaser, the revenue can be measured reliably and it is probable that the economic benefits relating to the sale will flow to the Company.

Revenue is measured at the consideration received and is recognised exclusive of VAT and net of discounts relating to sales.

Expenses for raw materials and consumables

Expenses for raw materials and consumables comprise the raw materials and consumables consumed to achieve revenue for the year.

Other external expenses

Other external expenses comprise indirect production costs and expenses for premises, sales and distribution as well as office expenses, etc.

Gross profit/loss

With reference to section 32 of the Danish Financial Statements Act, gross profit/loss is calculated as a summary of revenue, expenses for raw materials and consumables and other external expenses.

Notes to the Financial Statements

14 Accounting Policies (continued)

Staff expenses

Staff expenses comprise wages and salaries as well as payroll expenses.

Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses comprise amortisation, depreciation and impairment of intangible assets and equipment.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year.

Tax on profit/loss for the year

Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity.

The Company is jointly taxed with 2care4 Group ApS and all subsidiaries of the parent company. The tax effect of the joint taxation is allocated to enterprises in proportion to their taxable incomes.

Notes to the Financial Statements

14 Accounting Policies (continued)

Balance Sheet

Intangible assets

Intellectual property rights etc comprise development projects completed and in progress with related intellectual property rights and acquired intellectual property rights.

Development projects on clearly defined and identifiable products and processes, for which the technical rate of utilisation, adequate resources and a potential future market or development opportunity in the enterprise can be established, and where the intention is to manufacture, market or apply the product or process in question, are recognised as intangible assets. Other development costs are recognised as costs in the income statement as incurred. When recognising development projects as intangible assets, an amount equalling the costs incurred is taken to equity under Reserve for development costs that is reduced as the development projects are amortised and written down.

The cost of development projects comprises costs such as salaries and amortisation that are directly attributable to the development projects.

Completed development projects are amortised on a straight-line basis using their estimated useful lives which are determined based on a specific assessment of each development project. If the useful life cannot be estimated reliably, it is fixed at 10 years. For development projects protected by intellectual property rights, the maximum period of amortisation is the remaining duration of the relevant rights. The amortisation periods used are 5 years.

Intellectual property rights acquired are measured at cost less accumulated amortisation. Patents are amortised over their remaining duration, and licences are amortised over the term of the agreement, but over no more than 20 years.

Intellectual property rights etc are written down to the lower of recoverable amount and carrying amount.

Property, plant and equipment

Other fixtures and fittings, tools and equipment are measured at cost less accumulated depreciation and less any accumulated impairment losses.

Cost comprises the cost of acquisition and expenses directly related to the acquisition up until the time when the asset is ready for use.

Interest expenses on loans raised directly for financing the construction of property, plant and equipment are recognised in cost over the period of construction.

Depreciation based on cost reduced by any residual value is calculated on a straight-line basis over the

Notes to the Financial Statements

14 Accounting Policies (continued)

expected useful lives of the assets, which are:

Other fixtures and fittings, tools and equipment 3-5 years

The fixed assets' residual values are determined at nil.

Depreciation period and residual value are reassessed annually.

Impairment of fixed assets

The carrying amounts of intangible assets and property, plant and equipment are reviewed on an annual basis to determine whether there is any indication of impairment other than that expressed by amortisation and depreciation.

If so, the asset is written down to its lower recoverable amount.

Inventories

Inventories are measured at the lower of cost under the FIFO method and net realisable value.

The net realisable value of inventories is calculated at the amount expected to be generated by sale of the inventories in the process of normal operations with deduction of selling expenses. The net realisable value is determined allowing for marketability, obsolescence and development in expected selling price.

The cost of goods for resale, raw materials and consumables equals landed cost.

The cost of finished goods and work in progress comprises the cost of raw materials, consumables and direct labour.

Receivables

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts.

Equity

Dividend

Dividend distribution proposed by Management for the year is disclosed as a separate equity item.

Notes to the Financial Statements

14 Accounting Policies (continued)

Deferred tax assets and liabilities

Deferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes on the basis of the intended use of the asset and settlement of the liability, respectively.

Deferred tax assets are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. Any changes in deferred tax due to changes to tax rates are recognised in the income statement or in equity if the deferred tax relates to items recognised in equity.

Current tax receivables and liabilities

Current tax liabilities and receivables are recognised in the balance sheet as the expected taxable income for the year adjusted for tax on taxable incomes for prior years and tax paid on account. Extra payments and repayment under the on-account taxation scheme are recognised in the income statement in financial income and expenses.

Financial debts

Debts are measured at amortised cost, substantially corresponding to nominal value.